Skip to main content

Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients

Abstract

 The present multicenter study evaluated the clinical and bacteriological efficacy and safety of panipenem/betamipron (PAPM/BP) for treating pneumonia in elderly patients. Forty-three episodes of pneumonia in 43 patients were treated with PAPM/BP as the sole antibiotic agent. All patients were 65 years of age or older, and were given PAPM/BP at a total daily dosage range of 0.5–2.0 g. The clinical efficacy rate, expressed as a percentage of the total number of excellent and good responses, was 56.4%. Of the 43 patients, 13 were evaluated bacteriologically. In these 13 patients, the eradication rate, expressed as a percentage of the total number of “eradicated” and “replaced” efficacies, was 30.8%. Adverse effects and abnormal laboratory findings occurred in 2 patients, which was 4.6% of the total number of patients evaluated. No serious adverse effects were observed. We concluded that PAPM/BP was well tolerated overall, and was effective and safe for most of the elderly patients.

This is a preview of subscription content, access via your institution.

Author information

Affiliations

Authors

Additional information

Received: July 16, 2001 / Accepted: December 27, 2001

About this article

Cite this article

Shibuya, Y., Kitamura, S., Tani, G. et al. Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients. J Infect Chemother 8, 151–154 (2002). https://doi.org/10.1007/s101560200026

Download citation

  • Key words Panipenem/betamipron
  • Elderly patients
  • Pneumonia
  • Carbapenems
  • Imipenem